Are we finally ready for outpatient management of febrile neutropenia?
Saini
Shermini
S
Department of Pediatrics, Division of Hematology and Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Rosoff
Philip M
PM
D000553:Ambulatory Care / Q000191:economics / Q000379:methods; D000583:Amikacin / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D002443:Ceftriaxone / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D002648:Child; D002675:Child, Preschool; D003365:Costs and Cost Analysis; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007902:Length of Stay / Q000191:economics; D008297:Male; D008991:Monitoring, Physiologic; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy / Q000191:economics; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D010351:Patient Discharge / Q000191:economics; D011446:Prospective Studies; D012307:Risk Factors; D017751:Safety Management; D018805:Sepsis / Q000191:economics / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors
D000900:Anti-Bacterial Agents; D002443:Ceftriaxone; D000583:Amikacin